Kubra Durkan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kubra Durkan has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Ayfer Yurt Kilcar
Institute of Nuclear Sciences, Ege University, Bornova, Izmir, 35100, Türkiye
2 shared publications - Cigdem Ichedef
Ege University
2 shared publications Ashley F. Szczodroski
Research Division, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA
1 shared publicationAyca Tuncel
Nuclear Applications Ege University Institute of Nuclear Sciences Bornova Izmir Turkey
1 shared publication- Charles Jeffrey Smith
Research Division, Harry S. Truman Memorial Veterans’ Hospital, Columbia, MO 65201, USA
1 shared publication Elif Baris
Department of Pharmacology, Faculty of Medicine, Izmir University of Economics, Izmir, Turkey
1 shared publication
Latest Publications
- 1 March 2024
- Published by Bentham Science Publishers Ltd. in Current Radiopharmaceuticals
- Vol. 17 (1) , 91-98
Radiolabeling of Zonisamide for a Diagnostic Perspective
Objective:: Epilepsy is one of the oldest and the most common chronic neurological diseases. Antiepileptic drugs (AEDs) are the backbone of epilepsy treatment. However, epileptogenesis has not been fully elucidated. One of the critical reasons for this is the lack of reliable biomarkers. Neuroimaging suggests a non-invasive examination and investigation tool that can detect critical pathophysiological changes involved in epileptogenesis and monitor disease progression. In the current study, the radiolabeling potential of Zonisamide (ZNS) (the secondgeneration AED) with Technetium-99m (99mTc) is examined to neuroimage the epileptogenic processes by contributing to the development of potential radiotracers. Methods:: ZNS was labeled with 99mTc and the radiochemical yield of [99mTc]Tc-ZNS was determined with TLRC (Thin Layer Liquid Radio Chromatography and HPLRC (High Performance Liquid Radio Chromatography) radiochromatographic methods. In vitro behavior of [99mTc]Tc-ZNS was determined with time-dependent uptake of [99mTc]Tc-ZNS on the SHSY5Y human neuroblastoma cells. Results:: The radiochemical yield of [99mTc]Tc-ZNS was determined as 98.03 ± 1.24% (n = 6) according to radiochromatographic studies results. [99mTc]Tc-ZNS demonstrated 5.38 and 6.18 times higher uptake values than the control group on the human neuroblastoma SH-SY5Y cell line at 120 and 240 minutes, respectively. Conclusion:: This study showed that the current radiolabeled antiepileptic drug has a diagnostic potential to be used in imaging neurological processes.
- 1 March 2024
- Published by Bentham Science Publishers Ltd. in Current Radiopharmaceuticals
- Vol. 17 (1) , 91-98
Radiolabeling of Zonisamide for a Diagnostic Perspective
Objective:: Epilepsy is one of the oldest and the most common chronic neurological diseases. Antiepileptic drugs (AEDs) are the backbone of epilepsy treatment. However, epileptogenesis has not been fully elucidated. One of the critical reasons for this is the lack of reliable biomarkers. Neuroimaging suggests a non-invasive examination and investigation tool that can detect critical pathophysiological changes involved in epileptogenesis and monitor disease progression. In the current study, the radiolabeling potential of Zonisamide (ZNS) (the secondgeneration AED) with Technetium-99m (99mTc) is examined to neuroimage the epileptogenic processes by contributing to the development of potential radiotracers. Methods:: ZNS was labeled with 99mTc and the radiochemical yield of [99mTc]Tc-ZNS was determined with TLRC (Thin Layer Liquid Radio Chromatography and HPLRC (High Performance Liquid Radio Chromatography) radiochromatographic methods. In vitro behavior of [99mTc]Tc-ZNS was determined with time-dependent uptake of [99mTc]Tc-ZNS on the SHSY5Y human neuroblastoma cells. Results:: The radiochemical yield of [99mTc]Tc-ZNS was determined as 98.03 ± 1.24% (n = 6) according to radiochromatographic studies results. [99mTc]Tc-ZNS demonstrated 5.38 and 6.18 times higher uptake values than the control group on the human neuroblastoma SH-SY5Y cell line at 120 and 240 minutes, respectively. Conclusion:: This study showed that the current radiolabeled antiepileptic drug has a diagnostic potential to be used in imaging neurological processes.
- 1 June 2021
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 42 (6) , 285-293
In vitro evaluation of 99mTc-sultamicillin for infection imaging
Early detection of the site of infection non-invasively with radiolabeled molecules is important for the success of treatment. Technetium-99m labeled antibiotics have the potential to discriminate between bacterial infection and sterile inflammation. Sultamicillin is the tosylate salt of the double ester of sulbactam plus ampicillin. In this study, sultamicillin was labeled with Tc-99m according to the stannous chloride method. Quality control studies of radiolabeled sultamicillin were performed by radiochromatographic methods. In vitro binding assays were performed in live and heat-killed gram-positive Staphylococcus aureus and gram-negative Escherichia coli strains. The radiolabeling yield of Tc-99m-sultamicillin was determined as 97.8% +/- 3.1% (n = 5). The maximum bacterial uptake of Tc-99m-sultamicillin was 80.7% +/- 11.00% at 4 h for living S. aureus and 93.2% +/- 4.40% at 2 h for E. coli. Bacterial uptake study results show that sultamicillin has the potential to be a nuclear imaging agent, especially in infections caused by gram-negative E. coli and gram-positive S. aureus.
- 1 June 2021
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 42 (6) , 285-293
In vitro evaluation of 99mTc-sultamicillin for infection imaging
Early detection of the site of infection non-invasively with radiolabeled molecules is important for the success of treatment. Technetium-99m labeled antibiotics have the potential to discriminate between bacterial infection and sterile inflammation. Sultamicillin is the tosylate salt of the double ester of sulbactam plus ampicillin. In this study, sultamicillin was labeled with Tc-99m according to the stannous chloride method. Quality control studies of radiolabeled sultamicillin were performed by radiochromatographic methods. In vitro binding assays were performed in live and heat-killed gram-positive Staphylococcus aureus and gram-negative Escherichia coli strains. The radiolabeling yield of Tc-99m-sultamicillin was determined as 97.8% +/- 3.1% (n = 5). The maximum bacterial uptake of Tc-99m-sultamicillin was 80.7% +/- 11.00% at 4 h for living S. aureus and 93.2% +/- 4.40% at 2 h for E. coli. Bacterial uptake study results show that sultamicillin has the potential to be a nuclear imaging agent, especially in infections caused by gram-negative E. coli and gram-positive S. aureus.
- 9 June 2020
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 46 (7) , 1108-1113
Preparation of technetium-99m labeled ibuprofen by direct route and technetium-99m tricarbonyl route: a comparison of in vivo behaviors
In the current study, ibuprofen (ibu) which is a non-steroidal anti-inflammatory drug (NSAID) was radiolabeled with 99mTc using two different methods: stannous chloride method (direct route) and technetium-99m tricarbonyl [99mTc(CO)3]+ route. Thus, it’s aimed to investigate the radiolabeling potential of ibu for inflammation detection and to monitor if there is any difference in in vivo distribution depending on the radiolabeling route. Quality control studies of both radiolabeled ibu were performed by radiochromatographic methods (Thin Layer Liquid Radio Chromatography and High Performance Liquid Radio Chromatography). Radiolabeling yields of 99mTc-ibu and 99mTc(CO)3-ibu were determined as 99.05 ± 0.83% and 91.79 ± 3.30% (n = 5), respectively. Experimental lipophilicities of both radiolabeled ibu were determined. The biological behaviour of both radiolabeled ibu was investigated in healthy Albino Wistar male rats by in vivo biodistribution studies. It was seen that both radiolabeled ibuprofen showed renal excretion while organ uptakes of 99mTc-ibu and 99mTc(CO)3-ibu differ against time.
- 9 June 2020
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 46 (7) , 1108-1113
Preparation of technetium-99m labeled ibuprofen by direct route and technetium-99m tricarbonyl route: a comparison of in vivo behaviors
In the current study, ibuprofen (ibu) which is a non-steroidal anti-inflammatory drug (NSAID) was radiolabeled with 99mTc using two different methods: stannous chloride method (direct route) and technetium-99m tricarbonyl [99mTc(CO)3]+ route. Thus, it’s aimed to investigate the radiolabeling potential of ibu for inflammation detection and to monitor if there is any difference in in vivo distribution depending on the radiolabeling route. Quality control studies of both radiolabeled ibu were performed by radiochromatographic methods (Thin Layer Liquid Radio Chromatography and High Performance Liquid Radio Chromatography). Radiolabeling yields of 99mTc-ibu and 99mTc(CO)3-ibu were determined as 99.05 ± 0.83% and 91.79 ± 3.30% (n = 5), respectively. Experimental lipophilicities of both radiolabeled ibu were determined. The biological behaviour of both radiolabeled ibu was investigated in healthy Albino Wistar male rats by in vivo biodistribution studies. It was seen that both radiolabeled ibuprofen showed renal excretion while organ uptakes of 99mTc-ibu and 99mTc(CO)3-ibu differ against time.
- 1 February 2014
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 41 (2) , 133-139
A heterodimeric [RGD-Glu-[64Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors
- 1 February 2014
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 41 (2) , 133-139
A heterodimeric [RGD-Glu-[64Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors
- 31 August 2007
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 18 (5) , 1516-1520
Radiolabeling of Bombesin-Like Peptide with 99mTc: 99mTc-Litorin and Biodistribution in Rats
Bombesin-like peptides are related to several human cancer receptors, including small cell lung, prostate, breast, colon, and pancreatic cancers. Litorin, an amphibian bombesin peptide derivative, is found to stimulate the contraction of smooth muscle, to stimulate gastrin, gastric acid, and pancreatic secretion, and to suppress the nutriment in in vivo experiments. In the present study, litorin was labeled with 99mTc by the stannous chloride procedure. Labeling yield is 95 ± 1.4%, as determined by radio thin layer chromatography (RTLC) and radio high performance chromatography (RHPLC). Results of in vitro studies demonstrated a high stability in serum and cysteine solutions. In vivo biodistribution was investigated with normal male Albino Wistar rats. Biodistribution data showed fast clearance, low intestinal accumulation, and significant uptake in bombesin/gastrin releasing peptide (BN/GRP) receptor rich tissues such as the pancreas (23.56 ± 0.01 %ID/g 30 min pi). It can be blocked partially by previous administration of ‘cold' litorin. The results showed specificity of the uptake. As 99mTc-litorin displays good radiolabeling and biodistribution, it is a potentially useful radiopharmaceutical for detection of bombesin receptor-expressing cancers.
- 31 August 2007
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 18 (5) , 1516-1520
Radiolabeling of Bombesin-Like Peptide with 99mTc: 99mTc-Litorin and Biodistribution in Rats
Bombesin-like peptides are related to several human cancer receptors, including small cell lung, prostate, breast, colon, and pancreatic cancers. Litorin, an amphibian bombesin peptide derivative, is found to stimulate the contraction of smooth muscle, to stimulate gastrin, gastric acid, and pancreatic secretion, and to suppress the nutriment in in vivo experiments. In the present study, litorin was labeled with 99mTc by the stannous chloride procedure. Labeling yield is 95 ± 1.4%, as determined by radio thin layer chromatography (RTLC) and radio high performance chromatography (RHPLC). Results of in vitro studies demonstrated a high stability in serum and cysteine solutions. In vivo biodistribution was investigated with normal male Albino Wistar rats. Biodistribution data showed fast clearance, low intestinal accumulation, and significant uptake in bombesin/gastrin releasing peptide (BN/GRP) receptor rich tissues such as the pancreas (23.56 ± 0.01 %ID/g 30 min pi). It can be blocked partially by previous administration of ‘cold' litorin. The results showed specificity of the uptake. As 99mTc-litorin displays good radiolabeling and biodistribution, it is a potentially useful radiopharmaceutical for detection of bombesin receptor-expressing cancers.